Nanoparticulate systems for the delivery of antisense oligonucleotides

被引:151
|
作者
Lambert, G [1 ]
Fattal, E [1 ]
Couvreur, P [1 ]
机构
[1] Fac Pharm Chatenay Malabry, URA CNRS 8612, Lab Phys Chim Pharmacotech & Biopharm, F-92296 Chatenay Malabry, France
关键词
nanoparticles; nanocapsules; nanospheres; oligonucleotide; antisense;
D O I
10.1016/S0169-409X(00)00116-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Antisense oligonucleotides are molecules that are able to inhibit gene expression being therefore potentially active for the treatment of viral infections or cancer, However, because of their poor stability in biological medium and their weak intracellular penetration, colloidal drugs carriers such as nanoparticles were developed for the delivery of oligonucleotides (ODN). ODN associated to nanoparticles were shown to be protected against degradation and to penetrate more easily into different types of cells. As a consequence, nanoparticles were shown to improve the efficiency of ODNs for the inhibition of the proliferation of cells expressing the point mutated Ha-ras gene. In vivo, polyalkylcyanoacrylate (PACA) nanoparticles were able to efficiently distribute the ODNs to the liver whereas the alginate nanosponges could concentrate the ODNs in the lungs. Finally, ODN loaded to PACA nanoparticles were able to improve in mice, the treatment of RAS cells expressing the point mutated Ha-ras gene, (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:99 / 112
页数:14
相关论文
共 50 条
  • [1] Delivery systems for antisense oligonucleotides
    Garcia-Chaumont, C
    Seksek, O
    Grzybowska, J
    Borowski, E
    Bolard, J
    PHARMACOLOGY & THERAPEUTICS, 2000, 87 (2-3) : 255 - 277
  • [2] Development of delivery systems for antisense oligonucleotides
    Takakura, Y
    Mahato, RI
    Nomura, T
    Sawai, K
    Yoshida, M
    Kanamaru, T
    Hashida, M
    ADVANCED BIOMATERIALS IN BIOMEDICAL ENGINEERING AND DRUG DELIVERY SYSTEMS, 1996, : 357 - 358
  • [3] Cellular delivery of antisense oligonucleotides
    Lebedeva, I
    Benimetskaya, L
    Stein, CA
    Vilenchik, M
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2000, 50 (01) : 101 - 119
  • [4] LIPOSOMAL DELIVERY OF ANTISENSE OLIGONUCLEOTIDES
    THIERRY, AR
    DRITSCHILO, A
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1993, 6 (06): : 706 - 706
  • [5] In vitro delivery of antisense oligonucleotides
    Jääskeläinen, I
    Honkakoski, P
    Urtti, A
    CELLULAR & MOLECULAR BIOLOGY LETTERS, 2002, 7 (02) : 236 - 237
  • [6] Antisense oligonucleotides: strategies for delivery
    Miller, KJ
    Das, SK
    PHARMACEUTICAL SCIENCE & TECHNOLOGY TODAY, 1998, 1 (09): : 377 - 386
  • [7] Antisense oligonucleotides as therapeutics and their delivery
    Gurav, Bhagyashree
    Srinivasan, Ganga
    CURRENT SCIENCE, 2017, 112 (03): : 490 - 498
  • [8] Delivery of Antisense Oligonucleotides to the Cornea
    Chau, Viet Q.
    Hu, Jiaxin
    Gong, Xin
    Hulleman, John D.
    Ufret-Vincenty, Rafael L.
    Rigo, Frank
    Prakash, Thahza P.
    Corey, David R.
    Mootha, V. Vinod
    NUCLEIC ACID THERAPEUTICS, 2020, 30 (04) : 207 - 214
  • [9] Alternative delivery systems for antiviral nucleosides and antisense oligonucleotides to the brain
    Levy, RM
    Ward, S
    Schalgeter, K
    Groothuis, D
    JOURNAL OF NEUROVIROLOGY, 1997, 3 : S74 - S75
  • [10] Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics
    Ramasamy, Thiruganesh
    Ruttala, Hima Bindu
    Munusamy, Shankar
    Chakraborty, Nilay
    Kim, Jong Oh
    JOURNAL OF CONTROLLED RELEASE, 2022, 352 : 861 - 878